| 000 | 00999 a2200301 4500 | ||
|---|---|---|---|
| 005 | 20250516124146.0 | ||
| 264 | 0 | _c20130408 | |
| 008 | 201304s 0 0 eng d | ||
| 022 | _a1526-632X | ||
| 024 | 7 |
_a10.1212/WNL.0b013e31827b1b7c _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAlberts, Mark J | |
| 245 | 0 | 0 |
_atPA and warfarin: time to move forward. _h[electronic resource] |
| 260 |
_bNeurology _cFeb 2013 |
||
| 300 |
_a514-5 p. _bdigital |
||
| 500 | _aPublication Type: Editorial; Comment | ||
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 |
_aHemorrhage _xchemically induced |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 |
_aStroke _xdrug therapy |
| 650 | 0 | 4 | _aThrombolytic Therapy |
| 650 | 0 | 4 |
_aTissue Plasminogen Activator _xadministration & dosage |
| 650 | 0 | 4 |
_aWarfarin _xadministration & dosage |
| 700 | 1 | _aNaidech, Andrew M | |
| 773 | 0 |
_tNeurology _gvol. 80 _gno. 6 _gp. 514-5 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1212/WNL.0b013e31827b1b7c _zAvailable from publisher's website |
| 999 |
_c22330813 _d22330813 |
||